Perrigo Company plc Ordinary Shares (PRGO): Price and Financial Metrics
Perrigo Company plc Ordinary Shares (PRGO)
Today's Latest Price: $55.03 USD
Updated May 28 8:04pm
Add PRGO to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 214 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
PRGO Stock Summary
- PRGO has a higher market value than 83.47% of US stocks; more precisely, its current market capitalization is $7,569,481,103.
- PERRIGO Co plc's stock had its IPO on December 17, 1991, making it an older stock than 82.21% of US equities in our set.
- In terms of volatility of its share price, PRGO is more volatile than only 5.23% of stocks we're observing.
- Stocks with similar financial metrics, market capitalization, and price volatility to PERRIGO Co plc are HRC, XYL, WAB, LFUS, and CCMP.
- PRGO's SEC filings can be seen here. And to visit PERRIGO Co plc's official web site, go to www.perrigo.com.
PRGO Stock Price Chart More Charts
PRGO Price/Volume Stats
| Current price | $55.03 | 52-week high | $63.86 |
| Prev. close | $55.53 | 52-week low | $40.01 |
| Day low | $54.92 | Volume | 538,900 |
| Day high | $56.26 | Avg. volume | 1,232,262 |
| 50-day MA | $50.34 | Dividend yield | 1.62% |
| 200-day MA | $52.30 | Market Cap | 7.50B |
Perrigo Company plc Ordinary Shares (PRGO) Company Bio
Perrigo Company develops, manufactures, and distributes generic prescription pharmaceuticals, infant formulas, nutritional products, active pharmaceutical ingredients and pharmaceutical and medical diagnostic products. The company was founded in 1887 and is based in Dublin, Ireland.
PRGO Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $55.03 | $14.96 | -73% |
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for PERRIGO Co plc. To summarize, we found that PERRIGO Co plc ranked in the 19th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 73%. In terms of the factors that were most noteworthy in this DCF analysis for PRGO, they are:
- The company's balance sheet shows it gets 69% of its capital from equity, and 31% of its capital from debt. Its equity weight surpasses that of merely 23.34% of free cash flow generating stocks in the Healthcare sector.
- Its compound free cash flow growth rate, as measured over the past 5.73 years, is -0.09% -- higher than merely 17.97% of stocks in our DCF forecasting set.
- PERRIGO Co plc's weighted average cost of capital (WACC) is 7%; for context, that number is higher than only 18.29% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -74% |
| 1% | -73% |
| 2% | -73% |
| 3% | -73% |
| 4% | -73% |
| 5% | -72% |
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as PRGO, try AZN, ARA, CPIX, PBYI, and NRC.
Loading social stream, please wait...